The Complainant is the holding company of the Novartis Group, headquarter in Switzerland and, set up in 1996 through a merger of two companies becoming one of the biggest global pharmaceutical and healthcare groups in the world.
In 2024, the Novartis Group achieved net sales of USD 50.3 billion and, total net income amounted to USD 11.9 billion, having a number of approximately 76 000 employees as of December 31, 2024.
NOVARTIS trademark is to be considered as well-known for UDRP purposes.<\/p>\n
The Complainant owns multiple domain names consisting in the wording “novartis” and in combination of other terms, such as <novartis.com>, registered on April 2, 1996, <novartis.com.sg> registered on January 12, 2001, or <novartispharma.com> registered on October 27, 1999.<\/p>\n
The disputed domain name <novartispharmasingapore.com> was registered on June 23, 2025 and redirects to a parking page of the Registrar.
The Complainant sent on July 14, 2025 a cease-and-desist letter to the Respondent, via the Registrar, who did not reply.<\/p>",
"other_legal_proceedings": "
The Panel is not aware of any other legal proceedings which are pending or decided and which relate to the disputed domain name.<\/p>", "no_response_filed": "
THE COMPLAINANT
The Complainant contends that the requirements of the Policy have been met and that the disputed domain name should be transferred to it.
In particular, the Complainant alleges that the addition of the terms “pharma” and “singapore” cannot prevent a finding of confusingly similarity.
The Complainant also contends that none of the circumstances depicted in paragraph 4 (c) of the Policy applies in this case. Indeed, says the Complainant, the structure of the disputed domain name, reveals that the Respondent’s intention was to refer to the Complainant, its trademark and business activity and, to create an association and a subsequent likelihood of confusion with the Complainant and, its trademarks.
Furthermore, Complainant´s trademark is well-known and the inactive use support a finding of bad faith use and registration.<\/p>\n
THE RESPONDENT
No administratively compliant Response has been filed.<\/p>",
"rights": "
The Complainant has, to the satisfaction of the Panel, shown the disputed domain name is identical or confusingly similar to a trademark or service mark in which the Complainant has rights (within the meaning of paragraph 4(a)(i) of the Policy).<\/p>", "no_rights_or_legitimate_interests": "
The Complainant has, to the satisfaction of the Panel, shown the Respondent to have no rights or legitimate interests in respect of the disputed domain name (within the meaning of paragraph 4(a)(ii) of the Policy).<\/p>", "bad_faith": "
The Complainant has, to the satisfaction of the Panel, shown the disputed domain name has been registered and is being used in bad faith (within the meaning of paragraph 4(a)(iii) of the Policy).<\/p>", "procedural_factors": "
The Panel is satisfied that all procedural requirements under UDRP were met and there is no other reason why it would be inappropriate to provide a decision.<\/p>", "decision": "Accepted", "panelists": [ "Manuel Moreno-Torres" ], "date_of_panel_decision": "2025-11-07 00:00:00", "informal_english_translation": "
The Complainant owns a large portfolio of trademarks for NOVARTIS in several jurisdictions. As such, International Trademark with registration No. 663765, registered on July 1, 1996 or, the Intellectual Property India with registration No. 3574875, registered on July 17, 2017.<\/p>", "decision_domains": { "novartispharmasingapore.com": "TRANSFERRED" }, "panelist": null, "panellists_text": null }